Etoposide
Etopophos, Toposar, Vepesid (etoposide) is a small molecule pharmaceutical. Etoposide was first approved as Vepesid on 1983-11-10. It is used to treat brain neoplasms, ewing sarcoma, histiocytosis, kaposi sarcoma, and lung neoplasms amongst others in the USA. The pharmaceutical is active against DNA topoisomerase 2-alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Etopophos (generic drugs available since 1995-07-17, discontinued: Toposar, Vepesid)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Etoposide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VEPESID | CordenPharma | N-018768 DISCN | 1983-11-10 | 1 products, RLD |
| VEPESID | Strides Pharma Global | N-019557 DISCN | 1986-12-30 | 2 products, RLD |
Hide discontinued
Etoposide phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ETOPOPHOS PRESERVATIVE FREE | CHEPLAPHARM Arzneimittel | N-020457 RX | 1996-05-17 | 1 products, RLD, RS |
Show 1 discontinued
Indications
FDA
EMA
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
1791 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Small cell lung carcinoma | D055752 | — | — | 33 | 72 | 37 | 2 | 10 | 136 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 23 | 50 | 29 | 9 | 12 | 107 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 36 | 65 | 16 | 1 | 5 | 104 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 29 | 68 | 8 | 3 | 7 | 100 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 35 | 41 | 29 | 1 | 9 | 99 |
| Non-small-cell lung carcinoma | D002289 | — | — | 18 | 37 | 15 | 1 | 4 | 67 |
| Neoplasms | D009369 | — | C80 | 37 | 20 | 4 | 1 | 2 | 57 |
| T-cell lymphoma peripheral | D016411 | — | — | 12 | 17 | 2 | 1 | 4 | 32 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 12 | 20 | 4 | 1 | 3 | 32 |
| Burkitt lymphoma | D002051 | — | C83.7 | 13 | 17 | 1 | 2 | 3 | 32 |
Show 13 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 34 | 145 | 40 | — | 17 | 219 |
| Leukemia | D007938 | — | C95 | 31 | 67 | 38 | — | 7 | 128 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 24 | 53 | 26 | — | 4 | 95 |
| Hodgkin disease | D006689 | — | C81 | 25 | 53 | 14 | — | 6 | 79 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 19 | 31 | 21 | — | 5 | 72 |
| Myelodysplastic syndromes | D009190 | — | D46 | 20 | 22 | 12 | — | 3 | 50 |
| Multiple myeloma | D009101 | — | C90.0 | 7 | 31 | 9 | — | 5 | 48 |
| Sarcoma | D012509 | — | — | 10 | 22 | 12 | — | 2 | 44 |
| Central nervous system neoplasms | D016543 | — | — | 8 | 22 | 6 | — | 4 | 39 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 13 | 22 | 7 | — | 1 | 37 |
Show 74 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 6 | 12 | — | — | 5 | 20 |
| Plasma cell neoplasms | D054219 | — | — | 6 | 12 | — | — | 2 | 20 |
| Graft vs host disease | D006086 | — | D89.81 | 3 | 6 | — | — | 3 | 11 |
| Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | 3 | 5 | — | — | 2 | 9 |
| Lymphomatoid granulomatosis | D008230 | — | C83.8 | 4 | 4 | — | — | 3 | 9 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 3 | 4 | — | — | 3 | 8 |
| Primitive neuroectodermal tumors | D018242 | — | — | 2 | 2 | — | — | 3 | 7 |
| Aids-related lymphoma | D016483 | EFO_1001365 | — | 1 | 5 | — | — | 1 | 7 |
| Plasmablastic lymphoma | D000069293 | — | C83.3 | 5 | 4 | — | — | — | 6 |
| Hematologic neoplasms | D019337 | — | — | 1 | 5 | — | — | 1 | 6 |
Show 94 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Large granular lymphocytic leukemia | D054066 | — | — | 2 | — | — | — | 2 | 4 |
| Peritoneal neoplasms | D010534 | — | — | 2 | — | — | — | — | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | 1 | 2 |
| Promyelocytic leukemia acute | D015473 | — | C92.4 | 1 | — | — | — | 1 | 2 |
| Neuroepithelial neoplasms | D018302 | — | — | 1 | — | — | — | — | 1 |
| Mycosis fungoides | D009182 | — | C84.0 | 1 | — | — | — | — | 1 |
| Urethral neoplasms | D014523 | EFO_0003846 | — | 1 | — | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 1 | — | — | — | — | 1 |
| Deltaretrovirus infections | D006800 | EFO_1001303 | — | 1 | — | — | — | — | 1 |
Show 12 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chediak-higashi syndrome | D002609 | Orphanet_167 | D72.0 | — | — | — | — | 2 | 2 |
| Paroxysmal hemoglobinuria | D006457 | Orphanet_447 | D59.12 | — | — | — | — | 1 | 1 |
| Multiple primary neoplasms | D009378 | — | — | — | — | — | — | 1 | 1 |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | — | — | — | — | 1 | 1 |
| Peripheral blood stem cell transplantation | D036102 | — | — | — | — | — | — | 1 | 1 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | — | — | 1 | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | — | 1 | 1 |
| Electric stimulation therapy | D004599 | — | — | — | — | — | — | 1 | 1 |
| Wiskott-aldrich syndrome | D014923 | EFO_0003903 | D82.0 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Etoposide |
| INN | etoposide |
| Description | Etoposide is a beta-D-glucoside, a furonaphthodioxole and an organic heterotetracyclic compound. It has a role as an antineoplastic agent and a DNA synthesis inhibitor. It is functionally related to a podophyllotoxin and a 4'-demethylepipodophyllotoxin. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O |
Identifiers
| PDB | — |
| CAS-ID | 33419-42-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL44657 |
| ChEBI ID | 4911 |
| PubChem CID | 36462 |
| DrugBank | DB00773 |
| UNII ID | 6PLQ3CP4P3 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TOP2B
TOP2B
Organism
Homo sapiens
Gene name
TOP2B
Gene synonyms
NCBI Gene ID
Protein name
DNA topoisomerase 2-beta
Protein synonyms
antigen MLAA-44, DNA topoisomerase II, 180 kD, DNA topoisomerase II, beta isozyme, topo II beta, topoisomerase (DNA) II beta 180kDa, topoisomerase II beta, topoisomerase IIb, U937 associated antigen
Uniprot ID
Mouse ortholog
Top2b (21974)
DNA topoisomerase 2-beta (Q7TQG4)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Etoposide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 66,355 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
43,900 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use